Amphotericin B: Polyene Antifungal Antibiotic for Biofilm and Prion Research

Executive Summary: Amphotericin B is an amphipathic polyene antifungal antibiotic produced by Streptomyces nodosus, and is a research cornerstone for fungal infection and prion disease studies. Its mechanism involves selective interaction with ergosterol in fungal membranes, forming ion-permeable pores that induce cell death (APExBIO). Amphotericin B demonstrates an IC₅₀ range of 0.028–0.290 μg/ml in cell-based assays, evidencing high potency (APExBIO). In vitro, it triggers TLR2- and CD14-mediated cytokine release, modulating NF-κB signaling in immune cells (Shen et al. 2025). The compound also shows efficacy in in vivo prion disease models by reducing pathological prion protein accumulation. Its application is limited by solubility profile and mammalian toxicity due to cholesterol interaction.

Biological Rationale

Amphotericin B is classified as a polyene antifungal antibiotic. It is amphipathic (containing both hydrophilic and hydrophobic regions), which underlies its ability to interact with membrane sterols. Streptomyces nodosus produces Amphotericin B naturally. The compound's molecular weight is 924.08, and its chemical formula is C₄₇H₇₃NO₁₇ (APExBIO).

Fungal pathogens such as Candida albicans often form biofilms that are resistant to conventional antifungal agents (Shen et al. 2025). The emergence of multidrug-resistant fungi has increased the demand for agents with distinct mechanisms, including polyenes like Amphotericin B. In addition to antifungal effects, Amphotericin B has immunomodulatory properties, making it valuable for studying host-pathogen interactions and immune signaling pathways.

Mechanism of Action of Amphotericin B

Amphotericin B binds preferentially to ergosterol, the principal sterol in fungal cell membranes. Upon binding, it aggregates to form aqueous pores, increasing membrane permeability to small cations (e.g., K⁺, Na⁺) and anions (e.g., Cl^-). This disruption leads to leakage of cellular contents and cell death (APExBIO).

While ergosterol is the primary target, Amphotericin B can also bind to cholesterol in mammalian cells, which accounts for its cytotoxicity. In immune cells (e.g., macrophages, HEK293 cells expressing TLR2 and CD14), the compound induces inflammatory cytokine release by activating Toll-like receptor pathways and downstream NF-κB signaling (Shen et al. 2025).

Evidence & Benchmarks

• Amphotericin B shows an IC₅₀ of 0.028–0.290 μg/ml in cell-based antifungal assays, supporting its high potency (APExBIO, product page).
• In Candida albicans biofilm models, Amphotericin B overcomes some drug resistance mechanisms associated with autophagy and PP2A signaling (Shen et al. 2025).
• In vivo mouse models demonstrate that Amphotericin B-treated biofilms display reduced virulence and enhanced therapeutic response compared to controls (Shen et al. 2025).
• Amphotericin B reduces pathological prion protein (PrP^Sc) accumulation in transmissible spongiform encephalopathy (TSE) models, prolonging survival in infected animals (APExBIO, product page).
• The compound is soluble at ≥46.2 mg/mL in DMSO and insoluble in ethanol or water, restricting its formulation options (APExBIO).

This article extends the analysis in "Amphotericin B (SKU B1885): Reliable Solutions for Fungal...", by integrating recent peer-reviewed findings on biofilm resistance mechanisms and immune signaling, providing new molecular detail for advanced users.

For further mechanistic context, see "Reimagining Amphotericin B: Mechanistic Insights and Stra...". This current article clarifies the impact of autophagy and PP2A on resistance, documenting recent in vivo and in vitro benchmarks.

Applications, Limits & Misconceptions

Applications

• Fungal infection research: Used in cell viability, antifungal, and biofilm resistance assays with typical concentrations of 1–4 μg/mL (APExBIO).
• Immune signaling studies: Activates TLR2/CD14 and NF-κB pathways in immune cells (Shen et al. 2025).
• Prion disease models: Reduces PrP^Sc accumulation and extends survival in TSE animal models (APExBIO).
• Autophagy and resistance research: Enables benchmarking of drug resistance mechanisms in C. albicans biofilms (Shen et al. 2025).

Common Pitfalls or Misconceptions

• Misconception: Amphotericin B is effective against all fungal biofilms. Clarification: Some biofilms with autophagy activation may display partial resistance (Shen et al. 2025).
• Pitfall: Assuming solubility in aqueous buffers. Reality: Amphotericin B is insoluble in water and ethanol; use DMSO at ≥46.2 mg/mL for stock solutions (APExBIO).
• Limitation: Generalizing mammalian toxicity profile. Note: Toxicity arises due to cholesterol interaction in mammalian membranes; dosing must be carefully controlled (APExBIO).
• Boundary: Long-term storage of dissolved solutions. Best practice: Prepare fresh solutions; avoid long-term storage once dissolved (APExBIO).
• Hypothesis only: Use in non-fungal or non-prion models lacks sufficient evidence.

Workflow Integration & Parameters

Amphotericin B (SKU B1885) from APExBIO is supplied as a powder for research use. For experimental preparation, dissolve at ≥46.2 mg/mL in DMSO. Store stock solutions at -20°C; avoid repeated freeze-thaw cycles and long-term storage after dissolution (product page).

Recommended working concentrations for in vitro cell-based assays are 1–4 μg/mL. For in vivo models, dosing regimens should be validated according to study design and toxicity parameters. Amphotericin B can be used alongside autophagy modulators to evaluate resistance phenotypes, as described in recent biofilm research (Shen et al. 2025).

For troubleshooting and best practices, see "Amphotericin B (SKU B1885): Data-Driven Solutions for Fun...". The present article specifically updates on autophagy-driven resistance mechanisms and their impact on workflow design.

Conclusion & Outlook

Amphotericin B remains a vital tool for antifungal and prion research due to its unique mechanism of action and robust in vitro and in vivo efficacy. Its use in studying TLR2/CD14-mediated cytokine release and biofilm resistance mechanisms is increasingly relevant as multidrug-resistant pathogens emerge. Careful attention to formulation, storage, and concentration parameters is critical for reproducible results. APExBIO's Amphotericin B (SKU B1885) continues to enable cutting-edge research in fungal pathogenesis and therapeutic discovery.